Akhtar M, Calder M R, Corina D L, Wright J N
Biochem J. 1982 Mar 1;201(3):569-80. doi: 10.1042/bj2010569.
Mechanistic aspects of the biosynthesis of oestrogen have been studied with a microsomal preparation from full-term human placenta. The overall transformation, termed the aromatization process, involves three steps using O(2) and NADPH, in which the C-19 methyl group of an androgen is oxidised to formic acid with concomitant production of the aromatic ring of oestrogen: [Formula: see text] To study the mechanism of this process in terms of the involvement of the oxygen atoms, a number of labelled precursors were synthesized. Notable amongst these were 19-hydroxy-4-androstene-3,17-dione (II) and 19-oxo-4-androstene-3,17-dione (IV) in which the C-19 was labelled with (2)H in addition to (18)O. In order to follow the fate of the labelled atoms at C-19 of (II) and (IV) during the aromatization, the formic acid released from C-19 was benzylated and analysed by mass spectrometry. Experimental procedures were devised to minimize the exchange of oxygen atoms in substrates and product with oxygens of the medium. In the conversion of the 19-[(18)O] compounds of types (II) and (IV) into 3-hydroxy-1,3,5-(10)-oestratriene-17-one (V, oestrone), it was found that the formic acid from C-19 retained the original substrate oxygen. When the equivalent (16)O substrates were aromatized under (18)O(2), the formic acid from both substrates contained one atom of (18)O. It is argued that in the conversion of the 19-hydroxy compound (II) into the 19-oxo compound (IV), the C-19 oxygen of the former remains intact and that one atom of oxygen from O(2) is incorporated into formic acid during the conversion of the 19-oxo compound (IV) into oestrogen. This conclusion was further substantiated by demonstrating that in the aromatization of 4-androstene-3,17-dione (I), both the oxygen atoms in the formic acid originated from molecular oxygen. 10beta-Hydroxy-4-oestrene-3,17-dione formate, a possible intermediate in the aromatization, was synthesized and shown not to be converted into oestrogen. In the light of the cumulative evidence available to date, stereochemical aspects of the conversion of the 19-hydroxy compound (II) into the 19-oxo compound (IV), and mechanistic features of the C-10-C-19 bond cleavage step during the conversion of the 19-oxo compound (IV) into oestrogen are discussed.
已使用足月人胎盘的微粒体制剂研究了雌激素生物合成的机制。整个转化过程,即芳构化过程,使用氧气(O₂)和烟酰胺腺嘌呤二核苷酸磷酸(NADPH)分三步进行,其中雄激素的C-19甲基被氧化成甲酸,同时生成雌激素的芳环:[化学式:见原文] 为了从氧原子参与的角度研究该过程的机制,合成了许多标记前体。其中值得注意的是19-羟基-4-雄烯-3,17-二酮(II)和19-氧代-4-雄烯-3,17-二酮(IV),其中C-19除了用¹⁸O标记外还用²H标记。为了追踪芳构化过程中(II)和(IV)中C-19处标记原子的去向,将C-19释放的甲酸进行苄基化并通过质谱分析。设计了实验程序以尽量减少底物和产物中的氧原子与介质中的氧原子交换。在将(II)型和(IV)型的19-[¹⁸O]化合物转化为3-羟基-1,3,5-(10)-雌三烯-17-酮(V,雌酮)的过程中,发现C-19处的甲酸保留了原来底物中的氧。当等效的¹⁶O底物在¹⁸O₂下进行芳构化时,两种底物产生的甲酸都含有一个¹⁸O原子。有人认为,在将19-羟基化合物(II)转化为19-氧代化合物(IV)的过程中,前者的C-19氧保持完整,并且在将19-氧代化合物(IV)转化为雌激素的过程中,来自O₂的一个氧原子被并入甲酸中。通过证明在4-雄烯-3,17-二酮(I)的芳构化过程中,甲酸中的两个氧原子均来自分子氧,进一步证实了这一结论。合成了芳构化过程中的一种可能中间体甲酸10β-羟基-4-雌烯-3,17-二酮,并证明其不会转化为雌激素。根据迄今为止积累的证据,讨论了19-羟基化合物(II)转化为19-氧代化合物(IV)的立体化学方面,以及19-氧代化合物(IV)转化为雌激素过程中C-10-C-19键断裂步骤的机制特征。